Company Overview of Avelas BioSciences, Inc.
Avelas BioSciences, Inc. is a clinical stage biotechnology company that focuses on developing technologies that advance care for cancer surgery and therapeutic intervention. It develops AVB-620, an intravenously administered in vivo fluorescent protease-activatable peptide that detects, marks, and diagnoses cancer. The company was incorporated in 2008 and is based in La Jolla, California.
11099 North Torrey Pines Road
La Jolla, CA 92037
Founded in 2008
Key Executives for Avelas BioSciences, Inc.
Chief Executive Officer, President and Director
Co-Founder and Research Collaborator
Vice President of Clinical Affairs
Compensation as of Fiscal Year 2016.
Avelas BioSciences, Inc. Key Developments
Avelas Presents Phase 1b Clinical Trial Data for AVB-620
Dec 8 16
Avelas Biosciences, Inc. presented clinical trial data from the company's recently completed Phase 1b study in breast cancer patients utilizing investigational drug product AVB-620, at the San Antonio Breast Cancer Symposium. Jonathan Unkart, M.D., resident physician at Moores Cancer Center at UC San Diego Health, delivered the presentation titled "Intraoperative tumor detection using a ratiometric activatable fluorescent peptide: A first-in-human phase 1 study allows tumors to be visualized in the operating room" on behalf of himself and senior author Anne Wallace, M.D., Director of the Comprehensive Breast Health Center at Moores Cancer Center. The study represents the first-in-human experience with investigational drug product AVB-620, an activatable fluorescent peptide which is a potential adjunct in surgery for identifying tumors in real time. Dr. Unkart provided details on the safety and early results on proof-of-concept for the use of AVB-620 in identifying breast tumors during surgery. Specifically, no drug-related adverse events were noted in the trial and AVB-620 was able to achieve separation of tumor from adjacent tissues using a fluorescent image in both primary tumors and in lymph nodes.
Avelas BioSciences, Inc. Presents at 2016 BIO Investor Forum, Oct-19-2016 02:00 PM
Sep 15 16
Avelas BioSciences, Inc. Presents at 2016 BIO Investor Forum, Oct-19-2016 02:00 PM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States.
Avelas BioSciences, Inc. Completes Patient Enrollment for AVB-620 Phase 1b Clinical Trial
Sep 8 16
Avelas Biosciences, Inc. announced the completion of patient enrollment in its Phase 1b clinical trial for AVB-620, a surgical marker, in women with primary, non-recurrent breast cancer undergoing surgery. Avelas will announce data from the trial at a future medical meeting. AVB-620 Phase 1b Clinical Program: Fifteen patients were enrolled in the initial dose-escalation portion of the Phase 1b trial, the purpose of which was to evaluate safety and pharmacokinetics and to determine the dose for additional imaging analysis in the second stage of the study. Interim analysis showed no toxicity issues and identified a preferred dose to take forward into the expansion phase of the trial. A total of 12 additional patients have been enrolled in the dose-expansion stage of the trial, where the focus remains on safety, pharmacokinetics, and the timing of imaging after AVB-620 administration. The company expects to announce data from its completed Phase 1b trial later 2016. AVB-620 is an intravenously administered in vivo fluorescent protease-activatable peptide that detects, labels, and visualizes cancer. The initial potential use for AVB-620 is the intraoperative identification of primary tumor extent and metastatic lymph nodes in breast cancer patients. AVB-620 displayed outstanding preclinical data with sensitivity of greater than 95% in preclinical breast cancer models and ex vivo analysis of human breast cancer tissue.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 18, 2016